Renalytix PLC Renalytix to Present at H.C. Wainwright Conference
September 08 2022 - 2:01AM
RNS Non-Regulatory
TIDMRENX
Renalytix PLC
08 September 2022
Renalytix to Present at H.C. Wainwright 24th Annual Global
Investment Conference
NEW YORK, NY and SALT LAKE CITY, UT September 8, 2022 -
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
company will participate in a fireside chat at the H.C. Wainwright
24th Annual Global Investment Conference to be held September
12-14, 2022. Interested parties may access a live and archived
webcast of the presentation on the "Investors" section of the
Company's website at https://investors.renalytix.com beginning at
7:00 a.m. Eastern Time on September 12, 2022.
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics
and laboratory services company that is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
leadership team, with a combined 200+ years of healthcare and
in-vitro diagnostic experience, has designed its KidneyIntelX
laboratory-developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D
with early CKD stages 1-3. We believe that by understanding how
disease will progress, patients and providers can take action early
to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com .
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker Tel: 020 7710 7600
)
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303
/ Alice Woodings / 07407 804 654
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASSMFSWEESEDU
(END) Dow Jones Newswires
September 08, 2022 02:01 ET (06:01 GMT)
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Apr 2023 to Apr 2024